http://www.reuters.com/article/Health09 ... WY20091109
excerpt from the above article
Jimenez said the lower dose of oral multiple sclerosis drug FTY720, which Novartis plans to file with regulators next month, was "clearly approvable" and would be an attractive option for patients seeking an alternative to injections.
It is in a head-to-head race with Merck KGaA's (MRCG.DE: Quote, Profile, Research, Stock Buzz) cladribine to be the first oral MS drug on the market and the German group has stolen a march having already filed for approval in the United States.
TOL
FTY720 and cladribine filing info
- thinkingoutloud86
- Family Elder
- Posts: 122
- Joined: Wed May 31, 2006 2:00 pm
Thanks for the info TOL, but...
What are the release dates for these drugs? Did it say March for Cladribine? I couldn't tell when reading the link. 

Take care, Ewizabeth Previously Avonex, Rebif & Copaxone RRMS ~Tysabri, 31 infusions, ended 9/09. Starting Copaxone 12/09, waiting for Cladribine to be approved in 2010.
- thinkingoutloud86
- Family Elder
- Posts: 122
- Joined: Wed May 31, 2006 2:00 pm